| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
84,190,000 |
| Market
Cap: |
10.84(B) |
| Last
Volume: |
427,350 |
Avg
Vol: |
426,157 |
| 52
Week Range: |
$67.31 - $157.19 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 16.7 |
| Insider 3/6 Months : 17.3 |
|
| Guru Rank Number : 983 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Co. is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy, Limb-girdle muscular dystrophies and other neuromuscular and central nervous system related disorders. Co.'s commercial product, EXONDYS 51® (eteplirsen) Injection is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
75,225 |
143,757 |
247,027 |
| Total Buy Value |
$0 |
$5,942,300 |
$13,295,068 |
$24,257,422 |
| Total People Bought |
0 |
2 |
3 |
3 |
| Total Buy Transactions |
0 |
2 |
5 |
7 |
| Total Shares Sold |
24,096 |
24,096 |
39,096 |
39,954 |
| Total Sell Value |
$2,990,141 |
$2,990,141 |
$4,590,941 |
$4,685,252 |
| Total People Sold |
6 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
6 |
7 |
8 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Brown Ryan Edward |
SVP, General Counsel |
• – – |
2021-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
19,838 |
|
- |
|
| Estepan Ian Michael |
Chief Financial Officer |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$27,743 |
D/D |
(319) |
13,723 |
|
- |
|
| Oneill Gilmore Neil |
EVP, R&D & CMO |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$45,572 |
D/D |
(524) |
13,546 |
|
- |
|
| Brown Ryan Edward |
SVP, General Counsel |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$18,786 |
D/D |
(216) |
4,622 |
|
- |
|
| Rodino-Klapac Louise |
Chief Scientific Officer |
• – – |
2021-02-28 |
4/A |
D |
$86.97 |
$49,138 |
D/D |
(565) |
6,604 |
|
- |
|
| Brown Ryan Edward |
SVP, General CounselOfficer |
• – – |
2021-02-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,838 |
|
-9% |
|
| Rodino-Klapac Louise |
Chief Scientific OfficerOffice |
• – – |
2020-12-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,169 |
|
-57% |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-12-11 |
4 |
AS |
$165.00 |
$183,975 |
D/D |
(1,115) |
8,140 |
|
-58% |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-12-11 |
4 |
OE |
$71.45 |
$79,667 |
D/D |
1,115 |
9,255 |
|
- |
|
| Gray Mary Ann |
Director |
– • – |
2020-12-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
967 |
5,710 |
|
- |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-12-08 |
4 |
AS |
$160.00 |
$180,000 |
D/D |
(1,125) |
8,140 |
|
-55% |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-12-08 |
4 |
OE |
$29.60 |
$33,300 |
D/D |
1,125 |
9,265 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2020-08-10 |
4 |
S |
$158.95 |
$1,590,044 |
D/D |
(10,000) |
13,792 |
|
-11% |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2020-08-10 |
4 |
OE |
$34.92 |
$349,200 |
D/D |
10,000 |
23,792 |
|
- |
|
| Barry Richard |
Director |
– • – |
2020-08-07 |
4 |
S |
$158.43 |
$4,754,972 |
D/D |
(30,000) |
3,129,140 |
|
-10% |
|
| Bratica Joseph |
Principal Financial OfficerOff |
• – – |
2020-08-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,832 |
|
7% |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-08-03 |
4 |
AS |
$155.00 |
$174,375 |
D/D |
(1,125) |
7,832 |
|
7% |
|
| Bratica Joseph |
Principal Financial Officer |
• – – |
2020-08-03 |
4 |
OE |
$29.60 |
$33,300 |
D/D |
1,125 |
8,957 |
|
- |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2020-07-08 |
4 |
OE |
$13.71 |
$74,941 |
D/D |
3,806 |
20,260 |
|
- |
|
| Howton David T |
EVP, General Counsel |
• – – |
2020-06-22 |
4 |
AS |
$168.61 |
$17,962,831 |
D/D |
(105,122) |
31,871 |
|
-20% |
|
| Howton David T |
EVP, General Counsel |
• – – |
2020-06-22 |
4 |
OE |
$13.71 |
$2,708,440 |
D/D |
105,122 |
136,993 |
|
- |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2020-05-20 |
4 |
S |
$149.62 |
$753,210 |
D/D |
(5,000) |
13,792 |
|
6% |
|
| Wigzell Hans Lennart Rudolf |
Director |
– • – |
2020-05-20 |
4 |
OE |
$10.08 |
$50,400 |
D/D |
5,000 |
18,792 |
|
- |
|
| Barry Richard |
Director |
– • – |
2020-05-15 |
4 |
S |
$141.12 |
$4,237,946 |
D/D |
(30,000) |
3,159,140 |
|
-12% |
|
| Mahatme Sandesh |
EVP, CFO & CBO |
• – – |
2020-05-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,425 |
16,454 |
|
- |
|
360 Records found
|
|
Page 6 of 15 |
|
|
1.38 (1.08%) 
